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Background and objective: The effects of ambulatory oxygen for idiopathic pulmonary fibrosis
(IPF) patients without resting hypoxemia have not been elucidated. The purpose of this study
was to assess the effect of ambulatory oxygen on dyspnea in IPF patients without resting hyp-
oxemia but with desaturation on exertion.
Methods: This was a double-blind, placebo-controlled, randomized crossover trial of ambula-
tory oxygen versus ambulatory air. Patients with IPF who had a partial pressure of arterial
oxygen (PaO2) between 60 mm Hg and 80 mm Hg at rest, and desaturation of 88% or less in
a room-air 6-min walk test were eligible. Patients underwent a standardized 6-min walk test
and a 6-min free walk test under each ambulatory gas. Oxygen and air were provided at
4 L/min intranasally. Dyspnea was evaluated immediately, 1, and 2 min after the tests.
Results: Twenty patients (16 men), with a mean age of 73.5 (SD 4.1) years, % predicted forced
vital capacity (FVC) of 71.0 (13.3) %, % predicted diffusion capacity for carbon monoxide (DLco)
of 57.0 (13.3) %, and PaO2 of 72.5 (5.4) mm Hg were recruited. No significant differences in
dyspnea were observed between ambulatory oxygen and air at each time point. However,
some patients showed improvement in dyspnea with oxygen on an individual basis.366 0221; fax: þ81 367 7772.
dai.ac.jp, nishiyama_o@yahoo.co.jp (O. Nishiyama).
3 Elsevier Ltd. All rights reserved.
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1242 O. Nishiyama et al.Conclusions: Since oxygen provides no additional benefit over air in terms of exertional dys-
pnea for IPF patients without resting hypoxemia, routine prescription of ambulatory oxygen
is not recommended. However, assessment on an individual basis is necessary.
Trial registration. UMIN Clinical Trial Registry; No.:UMIN000005098; URL:http://www.umin.
ac.jp/ctr/.
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Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive
lung disease of unknown cause characterized by the histo-
pathological pattern of usual interstitial pneumonia [1].
The prognosis is poor, being roughly 3e4 years [2,3], and no
pharmacological therapies have been shown to improve
survival. As the disease progresses, dyspnea becomes se-
vere and activity of daily living can often seriously deteri-
orate in IPF patients.
When patients become hypoxemic (partial pressure of
arterial oxygen [PaO2] < 55 mmHg), long-term oxygen
therapy (LTOT) is usually recommended. The prescription
of LTOTwas originally based on 2 studies that demonstrated
mortality benefit of LTOT for patients with chronic
obstructive pulmonary disease (COPD) [4,5]. A Cochrane
review that summarized the effect of LTOT including later
studies also concluded that LTOT improved survival in COPD
patients with resting hypoxemia [6]. Given these reports, it
seems reasonable that IPF patients who have resting hyp-
oxemia undergo LTOT, although mortality benefit has not
been specifically demonstrated in IPF [7].
In general practices, clinicians often prescribe ambula-
tory oxygen for IPF patients without resting hypoxemia,
who experience hypoxemia during exercise or activities of
daily living. Actually, more severe desaturation occurs in
IPF patients when exercising than in COPD patients [8].
However, the effects of ambulatory oxygen for IPF patients
without resting hypoxemia but with exertional desaturation
have not been elucidated. Daily dyspnea is the major
contributing factor to the health-related quality of life of
these patients [9] and, furthermore, one of the prognostic
factors in IPF [10]. If oxygen alleviates dyspnea, it might be
possible to not only improve health-related quality of life
but also prolong longevity in IPF patients.
To assess the effect of oxygen on dyspnea after a 6-min
walk test in IPF patients without resting hypoxemia, we
designed a double-blind, placebo-controlled, randomized
crossover trial using ambulatory oxygen and ambulatory air.
Materials and methods
Patients
Patients with IPF were recruited from the Department of
Respiratory Medicine and Allergology, Kinki University Fac-
ulty of Medicine in Osaka-sayama, Japan. Eligible patients
were aged 20 yrs, with a PaO2 between 60 mmHg and
80 mmHg at rest, and with desaturation of 88% or less in a
room-air 6-min walk test. Disease was diagnosed according
to the criteria of the American Thoracic Society, EuropeanRespiratory Society, Japanese Respiratory Society, and Latin
American Thoracic Association for the diagnosis of IPF [1].
Patients were excluded if they had infection or acute
worsening of the disease within 3 months or unstable co-
morbid illnesses. We also excluded those patients who
could not undertake pulmonary function tests and 6-min
walk tests, those on more than 10 mg/day corticosteroids,
and those who were receiving LTOT for the purpose of
mortality reduction.
Written informed consent was obtained from every pa-
tient. The study protocol was approved by the ethics
committee of Kinki University Faculty of Medicine (No.
22e58).
Study design
The study was a double-blind, placebo-controlled, ran-
domized crossover trial using ambulatory oxygen and
ambulatory air. Patients underwent 2 different types of 6-
min walk tests on the first day under either ambulatory
intranasal oxygen or air: one was an ordinary standardized
test with an enthusiastic walk and the other was a free walk
test with a comfortable pace. Then, the patients were
crossed over to the other type of intranasal gas and un-
derwent the same walk tests on the next day. Allocation
was concealed from both the patients and the physicians
who supervised the walk tests. The order of pairs was
randomly determined. Ambulatory oxygen and placebo air
were provided at a rate of 4 L/min through nasal cannulas
using a demand oxygen delivery system (Fukuda Denshi,
Inc., Tokyo, Japan) [11,12].
Oxygen and placebo air were supplied by Fukuda Densi,
Inc., Tokyo, Japan. The shapes of the oxygen and placebo
air cylinders were completely the same but the colors were
different according to the Japanese law for medical gases
(black for oxygen and dark green for air). However, each
cylinder was covered with an identical sack so that the
subjects and physicians remained blinded to the treatment
group.
Outcomes
Patients completed 2 walk tests on the first and second days
of the study. The first test was an ordinary standardized 6-
min walk test, which was conducted according to the ATS
statement [13]. Briefly, patients were tested under stan-
dardized conditions by trained physicians while inhaling
ambulatory oxygen or placebo air. Patients wore a pulse
oximetry sensor (WristOx, NONIN, Inc., Minneapolis,
U.S.A.) on their wrist and baseline oxygen saturation and
heart rate were recorded by the coordinator; these results
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tests. Patients were instructed to walk as fast as possible up
and down a 30 m corridor for 6 min. The distance the pa-
tients could walk, as well as oxygen saturation and heart
rate immediately, 1, and 2 min after the test were recor-
ded. Furthermore, patients were asked to rate their dys-
pnea immediately, 1, and 2 min after the test, using the
modified Borg scale, by selecting a number from 0 to 10,
with 0 being no appreciable dyspnea and 10 being maximal
sustainable dyspnea [14]. Physicians did not walk with the
patients to minimize encouraging effects. A warm-up test
was not performed because all patients had already un-
dertaken an ordinary 6-min walk test without any ambula-
tory gas before the study walk, in order to confirm
desaturation.
The second test was a 6-min free walk test in which the
patients were instructed to walk at a pace that “they found
comfortable and would use to walk on a day to day basis”.
The same values as those measured for the ordinary 6-min
walk test were recorded.Data analysis
Continuous variables were summarized as mean (standard
deviation [SD]). Categorical variables were summarized as
counts and percentages. Dyspnea and leg fatigue after walk
tests, assessed with the modified Borg scale [14], were
analyzed as continuous variables. An unpaired t test was
performed to make comparisons between the oxygen and
placebo air group.
An original sample size of 20 was determined to detect a
reduction of 1 in the modified Borg scale after walk tests,
which has been reported to be the minimal clinically
important difference [15], with oxygen as compared to
placebo air. The sample size provided a statistical power of
80%, allowing for a type I error of 0.05.
All statistical analyses were performed using the PASW
statistical package, version 18 (SPSS Japan Inc., Tokyo,
Japan). A P value less than 0.05 was considered statistically
significant.Results
Patients
All 20 patients who were identified as eligible between
February 2011 and April 2012 were included in the study
(Fig. 1). The characteristics of these 20 patients are shown in
Table 1. The mean age was 73.5 years and 80% of the pa-
tients (16/20) were male. No patients were already receiving
LTOT for mortality reduction or symptom relief. The mean
forced vital capacity (FVC) at recruitment was 2.1 L (71%
predicted), mean diffusion capacity for carbon monoxide
(DLco) was 8.3 mL min1 mmHg1 (57% predicted), and mean
PaO2 was 73 mm Hg. The results of an ordinary 6-min walk
test conducted before the study without any ambulatory
gases included a mean walk distance of 400 m, a mean
desaturation of 80%, and a mean dyspnea rating assessed
with the modified Borg scale of 5.7. There were no statisti-
cally significant differences in baseline variables betweenthose who underwent walk tests with oxygen first and those
who received placebo air first.
Outcomes of walk tests
In the ordinary standardized 6-min walk test, ambulatory
oxygen significantly improved oxygen saturation immedi-
ately, 1, and 2 min after the test (Table 2). However, ox-
ygen did not significantly improve walk distance or other
walk test outcomes including heart rate, dyspnea rating,
and leg fatigue. The results of the 6-min free walk test
were similar and oxygen did not significantly improve walk
test outcomes, except oxygen saturation after the test
(Table 3).
Individual changes in dyspnea rating with oxygen and
placebo air immediately after the 2 walk tests are shown in
Table 4. An improvement in dyspnea of 1 or more with
ambulatory oxygen, which has been shown to be the mini-
mal clinically important difference of the modified Borg
scale [15], was shown in 6 patients (33%) (patient nos. 4, 7,
9, 10, 13, and 17) and 8 patients (40%) (patient nos. 1, 2, 3,
7, 8, 9, 17, and 18) after the ordinary standardized 6-min
walk test and the 6-min free walk test, respectively. On
the other hand, worsening in dyspnea with oxygen was
observed in 4 patients (20%) (patient nos. 8, 11, 12, and 14)
and 5 patients (25%) (patient nos. 5, 12, 15, 16, and 20)
after the ordinary and free walk tests, respectively.
Discussion
The current study is, to our knowledge, the first placebo-
controlled, double-blind study with a crossover design that
has examined the effect of ambulatory oxygen on exer-
tional dyspnea in IPF. The results showed that ambulatory
oxygen with a flow rate of 4 L/min did not improve dyspnea
after a standardized 6-min walk test or after a 6-min free
walk. Furthermore, oxygen did not cause significant
improvement in walk distance, leg fatigue, or heart rate in
both tests.
The effect of oxygen on dyspnea in COPD had been
investigated in several studies [16e23]. Although oxygen
improves exercise performance, its reported effects on
dyspnea are conflicting. A Cochrane review demonstrated a
statistically significant effect of oxygen on dyspnea in COPD
patients without resting hypoxemia, but the effect size was
marginal [24]. Recently, 2 randomized studies that tested
the effect of oxygen on dyspnea in patients without resting
hypoxemia were reported. However, the results showed
that oxygen confers no benefit on daily dyspnea in COPD
[25,26].
As for IPF, a few studies have examined the effect of
oxygen. Only 1 randomized controlled trial reported a
favorable effect of oxygen in interstitial lung disease [27],
but this study included patients with conditions other than
IPF and the patient population comprised those with resting
hypoxemia. Two recent studies showed conflicting results
[28,29], but these were based on retrospective observations.
Therefore, the present study is the first to test the effect of
oxygen in a randomized controlled fashion specifically in IPF
patients without resting hypoxemia. However, the results
were negative.
Figure 1 Study profile.
Table 2 Ordinary 6-min walk test results with ambulatory
oxygen and placebo air.
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lung diseases, such as IPF are complex and multi-factorial
[30]. Not only oxygenation but also ventilatory demand,
respiratory and peripheral muscle function, and cardio-
vascular factors can affect when patients feel dyspnea.
This is also suggested by the fact that dyspnea rating
assessed with the modified Borg scale ranged widely be-
tween extremities as shown in Table 4, although the
severity of disease was mild-to-moderate in every patient.
The negative results in the present study suggest that
desaturation is not the major factor for dyspnea in IPF as a
whole, although more severe desaturation in IPF than in
COPD has been reported [8]. Routine prescription of oxygen
should be avoided because the effect of oxygen on dyspnea
is not statistically significant and redundancy of ambulatory
oxygen can worsen health-related quality of life of patients
by leading them to be house-bound. Furthermore, inade-
quate use of domiciliary and ambulatory oxygen generates
substantial costs.Table 1 Patient characteristics (n Z 20).
Characteristics Mean (SD) or %
Age, yrs 73.5 (4.1)
Male gender, % 80.0
FVC, L 2.1 (0.4)
FVC, % predicted 71.0 (13.3)
DLco, mL min1 mmHg1 8.3 (2.4)
DLco, % predicted 57.0 (13.2)
PaO2, mm Hg 72.5 (5.4)
6-min walk test
Distance, m 400 (87)
Minimum O2 saturation, % 79.9 (6.3)
Heart rate, bpm 113 (15)
Dyspnea 5.7 (2.3)
Leg fatigue 3.4 (2.6)
FVC: forced vital capacity; DLco: diffusion capacity for carbon
monoxide; PaO2: partial pressure of arterial oxygen; bpm: beats
per minutes.
Dyspnea and leg fatigue were assessed with the modified Borg
scale.It is interesting, however, that there were some patients
whose dyspnea improved by more than 1 on the Borg scale
with ambulatory oxygen, a change which has been consid-
ered to be clinically significant [15]. Three patients experi-
enced an improvement in dyspnea of 2 or more on the
modified Borg scale in the standardized 6-min walk test and
the 6-min free walk test. These patients could be so-called
responders. This result might mean that desaturation con-
tributes to dyspnea greatly in selective patients and that
these patients may benefit from ambulatory oxygen to
alleviate dyspnea. Daily dyspnea has been reported to be the
most important factor determining health-related quality of
life in IPF [9]. In selected patients with IPF, even without
resting hypoxemia, oxygen can reduce dyspnea and improve
health-related quality of life. An assessment of the effect ofVariables Oxygen Placebo air P value
n Z 20 n Z 20
Walk distance, m 400 (80) 387 (80) 0.61
Immediately after test
O2 saturation, % 84 (5) 80 (6) 0.02
Heart rate, bpm 116 (15) 110 (13) 0.24
Dyspnea 5.8 (2.2) 6.2 (2.2) 0.57
Leg fatigue 3.4 (2.5) 3.6 (2.5) 0.73
One minute after test
O2 saturation, % 90 (6) 83 (6) 0.0005
Heart rate, bpm 105 (15) 104 (12) 0.93
Dyspnea 3.9 (2.4) 4.2 (2.2) 0.66
Leg fatigue 2.4 (2.3) 2.0 (2.2) 0.65
Two minutes after test
O2 saturation, % 96 (3) 91 (4) 0.0002
Heart rate, bpm 96 (14) 95 (12) 0.69
Dyspnea 2.3 (1.8) 2.8 (2.1) 0.42
Leg fatigue 1.4 (1.9) 1.3 (1.9) 0.87
bpm: beats per minute.
Dyspnea and leg fatigue were assessed with the modified Borg
scale.
Table 3 Six-min free walk test results with ambulatory
oxygen and placebo air.
Variables Oxygen Placebo air P value
n Z 20 n Z 20
Walk distance, m 328 (57) 322 (70) 0.78
Immediately after test
O2 saturation, % 89 (6) 83 (6) 0.004
Heart rate, bpm 106 (15) 108 (12) 0.67
Dyspnea 3.8 (2.6) 4.4 (2.4) 0.49
Leg fatigue 2.5 (2.6) 2.4 (2.4) 0.98
One minute after test
O2 saturation, % 92 (5) 86 (6) 0.003
Heart rate, bpm 99 (15) 104 (15) 0.35
Dyspnea 2.7 (2.5) 2.5 (2.1) 0.84
Leg fatigue 1.5 (2.1) 1.3 (1.7) 0.71
Two minutes after test
O2 saturation, % 96 (2) 92 (4) <0.0001
Heart rate, bpm 94 (15) 96 (14) 0.64
Dyspnea 1.6 (1.8) 1.8 (1.6) 0.65
Leg fatigue 1.2 (2.0) 0.8 (1.4) 0.50
bpm: beats per minute.
Dyspnea and leg fatigue were assessed with the modified Borg
scale.
Ambulatory oxygen in IPF 1245oxygen should be undertaken individually before its pre-
scription for the purpose of symptom relief in IPF patients
without resting hypoxemia. However, it is difficult assess if







Oxygen Placebo air Oxygen Placebo air
1 7 7 2 4
2 6 7 4 5
3 10 10 7 10
4 4 5 4 4
5 5 5 4 1
6 7 7 5 5
7 2 4 0 4
8 7 6 4 5
9 7 9 6 7
10 4 5 2 2
11 5 4 1 0.5
12 5 4 5 4
13 5 7 7 7
14 2 1 0 0.5
15 7 7 6 5
16 7 7 5 4
17 4 7 0.5 6
18 4 4 0.5 2
19 7 7 4 4
20 10 10 9 7
Dyspnea was assessed with the modified Borg scale.practice. It might be, at least, necessary to make a com-
parison between walking with and without oxygen for eval-
uation of the effect of ambulatory oxygen on dyspnea and
walk distance in practice, although a placebo effect cannot
be fully excluded in this situation.
We evaluated dyspnea after 2 types of the walk tests.
Since the standardized 6-min walk test is considered to be a
sub-maximal exercise test [13], dyspnea after this walk test
might not accurately reflect the dyspnea experienced in
daily living. Therefore, we also evaluated dyspnea after a
6-min free walk, in which the patients walked at a pace
that they used on a day to day basis; however, the result
was the same as the standardized 6-min walk test. Although
the short-term effect of oxygen on dyspnea was negative in
the present study, its long-term effect on daily dyspnea
should be investigated in further studies using both sta-
tionary and ambulatory oxygen.
This study has some limitations. First, the sample size was
small. However, the number of patients was calculated so
that a difference of 1 on the modified Borg scale would be
detected with a statistical power of 80%. The detected dif-
ferences in dyspnea were 0.2e0.6 in the current study. If
more patients were recruited and statistical significance was
reached, this small improvement in dyspnea is still less than
the minimal clinically important difference and so is not
practically relevant. Second, the small sample size from one
center might have led to a selection bias. Third, adequate
oxygenation was not maintained after the standardized 6-
min walk test in the oxygen group, because the mean oxygen
saturation immediately after the test was 84% even when
using ambulatory oxygen. We used a flow rate of 4 L/min
with a demand oxygen delivery system [11,12] because a
high flow rate was not practical. It is possible that a higher
flow rate of oxygen might have led to a different result.
However, given that oxygenation above 88% at 1 and 2 min
after the standardized 6-min walk test and each point after
the free walk test did not produce symptom relief, a positive
effect of a higher rate of oxygen would be improbable.
Finally, the patients consisted of those with mild-to-
moderate functional impairments only. Two retrospective
observational reports which showed conflicting results con-
sisted of patients with moderate-to-severe impairments such
as 51e58% of % predicted FVC and 25e32% of % predicted
DLco, although these patients were without resting hypox-
emia. The results from the present study may not be applied
to severe patients; however, there may not be many patients
who have severe impairment without resting hypoxemia.
In conclusion, this randomized controlled trial found that
ambulatory oxygen provided no additional benefit over air in
terms of dyspnea after an ordinary standardized 6-min walk
test and a 6-min free walk in IPF patients. Our findings
suggest that routine prescription of ambulatory oxygen for
the purpose of symptom relief is not recommended in IPF
patients without resting hypoxemia, even if they have ex-
ertional desaturation. However, some patients can benefit
on an individual basis. An assessment of the effect of oxygen
should be made individually before prescription.Conflict of interest
None declared.
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